Mabswitch Inc SBIR Phase II award

Department of Health and Human Services, through National Institutes of Health, awarded Mabswitch Inc of Van Nuys, CA $399,998 under the SBIR program (Phase II), with work starting 2026-09-18 and running to 2027-08-31. It is one of 2 SBIR and STTR awards Mabswitch Inc received in the last two years, $799,990 in all. Each figure links to the federal record.

The award

Want the whole picture on Mabswitch Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Mabswitch Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Mabswitch Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What it is for

Remote-controlled pc-car t-cell therapy for hard-to-treat solid tumors - project summary chimeric antigen receptor (car) t-cell therapies have revolutionized blood cancer treatment but remain ineffective in solid tumors

Funding actions on this award

Remote-controlled pc-car t-cell therapy for hard-to-treat solid tumors - project summary chimeric antigen receptor (car) t-cell therapies have revolutionized blood cancer treatment but remain ineffective in solid tumors due to the scarcity of tumor-specific surface antigens. Many oncogenic drivers reside intracellularly and can only be targeted via peptides presented on major histocompatibility complex (mhc) molecules. However, peptide-mhc complexes are often poorly expressed, and tumors employ immune evasion strategies, limiting antigen availability. This challenge is particularly pronounced in low-mutational burden (tmb) cancers such as neuroblastoma, where traditional car-t and t-cell receptor (tcr)-t therapies struggle. Peptide-centric cars (pc-cars) have emerged as a promising solution, enabling recognition of intracellular tumor antigens via mhc presentation. However, fixed-affinity pc-cars face key challenges, including antigen escape, cross-reactivity, hyperactivation, and exhaustion. To overcome these limitations, mabswitch will develop remote-controlled pc-cars (rpc-cars) targeting a key neuroblastoma oncoprotein using its universal affinity switch for antibodies (unasma) technology. This system allows real-time modulation of car affinity, enhancing efficacy while mitigating toxicity. Specific aim 1 focuses on engineering rpc-cars with switchable affinity. These const ...

From the federal award record.

Other SBIR and STTR awards to Mabswitch Inc

Where this comes from

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.

Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.

All SBIR and STTR awards